Virtus ETF Advisers’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-32,688
| Closed | -$1.13M | – | 369 |
|
|
2020
Q3 | $1.13M | Buy |
32,688
+2,753
| +9% | +$58.6K | 0.59% | 55 |
|
|
2020
Q2 | $500K | Buy |
29,935
+11,135
| +59% | +$189K | 0.24% | 148 |
|
|
2020
Q1 | $271K | Sell |
18,800
-1,586
| -8% | -$40.5K | 0.11% | 238 |
|
|
2019
Q4 | $682K | Buy |
20,386
+7,752
| +61% | +$217K | 0.11% | 156 |
|
|
2019
Q3 | $265K | Sell |
12,634
-704
| -5% | -$14.4K | 0.05% | 208 |
|
|
2019
Q2 | $278K | Buy |
13,338
+1,345
| +11% | +$27.7K | 0.06% | 252 |
|
|
2019
Q1 | $268K | Sell |
11,993
-1,694
| -12% | -$39.9K | 0.57% | 70 |
|
|
2018
Q4 | $327K | Sell |
13,687
-2,206
| -14% | -$57.1K | 0.06% | 92 |
|
|
2018
Q3 | $434K | Sell |
15,893
-11,359
| -42% | -$321K | 0.04% | 148 |
|
|
2018
Q2 | $733K | Buy |
27,252
+5,151
| +23% | +$158K | 0.65% | 82 |
|
|
2018
Q1 | $703K | Buy |
22,101
+11,765
| +114% | +$414K | 0.61% | 94 |
|
|
2017
Q4 | $391K | Sell |
10,336
-7,562
| -42% | -$244K | 0.49% | 60 |
|
|
2017
Q3 | $444K | Buy |
17,898
+1,637
| +10% | +$35.3K | 0.06% | 100 |
|
|
2017
Q2 | $334K | Buy |
16,261
+3,789
| +30% | +$72.3K | 0.05% | 94 |
|
|
2017
Q1 | $271K | Buy |
12,472
+1,196
| +11% | +$24.5K | 0.05% | 151 |
|
|
2016
Q4 | $231K | Sell |
11,276
-8,225
| -42% | -$168K | 0.07% | 160 |
|
|
2016
Q3 | $293K | Hold |
19,501
| – | – | 0.14% | 102 |
|
|
2016
Q2 | $211K | Buy |
19,501
+5,835
| +43% | +$79.3K | 0.16% | 132 |
|
|
2016
Q1 | $185K | Buy |
+13,666
| New | +$213K | 0.25% | 97 |
|
Virtus ETF Advisers's AIMT Position: Q4 2020 in Review
Virtus ETF Advisers sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 32,688 shares — an estimated $1.13M sold.
Virtus ETF Advisers first reported a position in AIMT in Q1 2016 and held it in 19 quarters. The position peaked at $1.13M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Virtus ETF Advisers reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Virtus ETF Advisers sold 32,688 Aimmune Therapeutics shares in Q4 2020, an estimated $1.13M.
- Virtus ETF Advisers first reported a position in Aimmune Therapeutics in Q1 2016 and held it in 19 quarters.
- Virtus ETF Advisers's Aimmune Therapeutics position peaked at $1.13M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.